"Expert Shines Light on Novel Therapies Under Study for Food Allergy' - Gwen Smith
The FDA is considering approval of the AR101 peanut immunotherapy and will soon evaluate the Viaskin peanut patch. But if you wonder what else is in the therapeutic pipelines for food allergy the answer is: plenty. Those attending the presidential plenary session of the AAAAI allergists’ conference in late February heard a comprehensive overview of the research from Cecilia Berin, PhD, professor of pediatrics at the Icahn School of Medicine at Mount Sinai, whose own research delves into the mechanisms of the food-allergic response. She walked allergists through several novel therapy strategies under study, leaving the audience hopeful for the possibilities ahead. “Ten years ago, we had very little in the pipeline and, in contrast now, we have a wealth of potential approaches,” said Dr. Berin.
— Cecilia Berin, PhD, Professor, Pediatrics, Icahn School of Medicine at Mount Sinai